Telix Pharmaceuticals

(AI video summary)

This video was created on 21 January 2026 for IG audiences by ausbiz.

ASX code: TLX

Record growth but muted reaction

Telix Pharmaceuticals has reached a major milestone, meeting its financial year (FY) 2025 target with approximately $1.2 billion in unaudited revenue. Revenue in the fourth quarter (Q4) rose 46% quarter-on-quarter (QoQ) to a record $322 million, highlighting continued momentum in the company’s nuclear medicine business

Strong demand for its prostate cancer imaging product, Illuccix, drove the result, but the share price still fell 5.7% in early trade. Illuccix now holds around 55% of the Australian prostate cancer diagnostic tracer market, reinforcing its domestic leadership position.

Regulatory progress supports global expansion

International growth remains a key focus. China’s regulator has accepted a new drug application for Illuccix, while additional marketing authorisations have been secured across Europe. These regulatory milestones strengthen Telix’s global footprint and support its longer-term growth ambitions.

Investment outlook

Attention is now shifting to the development pipeline as the next potential catalyst. While Telix generates substantial revenue, recent regulatory progress has had limited impact on sentiment. Caution is reinforced by short interest near 10% and ongoing director share sales, with volatility expected to rise into February’s reporting season.